According to data from Morningstar, the Frazis Fund has rocketed 83% from its April 17 low to July 18 as the high-octane investor’s big bets on semiconductors, superclusters, next-gen biotech and Reddit\u00a0(NYSE: RDDT) paid off handsomely.\u00a0<\/p>\n
![\"Mike](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/08\/Mike-Frazis-wire_inline.jpg\")
<\/p>\n
Mike Frazis says his fund has climbed more than 80% since President Trump spooked markets by launching a chaotic trade war on April 2.\u00a0<\/p>\n
“Nvidia has been the easiest way to invest in AI, but there are a number of higher-returning opportunities in smaller companies that are growing faster than the sector,” he says.\u00a0<\/p>\n
“We had companies like Credo and Astera Labs. If you look at those charts, you’ll see over 100% moves [since April]. We also bought some of the fallen angels – so companies like Elf Beauty and Transmedics that dropped 60% or 70%, but then also recovered over 100% from the April lows.”<\/p>\n
He also says internet rabbit hole and social news aggregator Reddit\u00a0is posting growth rates to justify its 255% share price rise over the past 12 months.\u00a0<\/p>\n
“If you search on Google now, you’ll get Reddit results,” he says. “That authentic conversation [on Reddit] around niche issues is also helpful to AI. Users are growing 21% and revenue growth was up 78% for the June quarter. Gross margin 91%. It’s a really good ad business, growing fast. So there are different ways to invest in AI.”<\/p>\n
Risk management<\/p>\n
Frazis says he’s now confident in the potential of his in-house AI systems to manage downside, and even adds that their price-modelling signals would’ve saved his investors from 2022’s horror run.<\/p>\n
“If we had these systems in January 2022, we would’ve sold and moved to cash, then it could’ve been a great year for us, as we would’ve got back into the market in January 2023,” he says.\u00a0<\/p>\n
“So we’ll stay volatile and high risk\/return, but we’ve got a structured process to move to cash during sell-offs and to re-enter the market.”<\/p>\n
Overall, Mr Frazis says he expects the latest unit pricing will show the fund is up around 41% net of fees over calendar year 2025.\u00a0<\/p>\n
Biotech bets<\/p>\n
The stock picker, who boasts a chemistry degree from the University of Oxford, has also profited from a dramatic rebound in the ASX biotech sector, as investors’ risk appetite returned on a pivot to the TACO (Trump Always Chickens Out) trade.\u00a0<\/p>\n
Three of the Frazis Fund’s ASX holdings include\u00a0Amplia Therapeutics (ASX: ATX<\/a>), Syntara Ltd (ASX: SNT<\/a>) and Clarity Pharmaceuticals (ASX: CU6<\/a>). They have all surged since President Trump’s April 2\u00a0Liberation Day shattered investors’ confidence before it returned with gusto.<\/p>\n “In both Amplia and Clarity, we invested in their recent capital raises,” says Frazis. “We’ve now put $30 million into pre-revenue Australian biotech. Amplia is developing treatments for pancreatic cancer. It announced two complete responses in [patients] in a small trial.”<\/p>\n Exchange-traded fund plans<\/p>\n Looking ahead, the investor will soon bring his brash style directly to the ASX as he plans to launch an exchange-traded fund tipped to hit the boards under the ticker ROAR in a nod to lions and their symbolic association with boldness.\u00a0\u00a0<\/p>\n The ETF will hold around 20-25 US businesses on market caps of at least US$1 billion, with an October 1 date pencilled in to ring the bell on its launch.\u00a0<\/p>\n Never miss an update<\/p>\n